Skip to content

Integer Holdings

US · ITGR #2239 by market cap Listed 1970
126.59 +0.12 +0.09%
Live - 5344 symbols - heartbeat 185s ago · 2026-10-07 19:54
After-hours 126.57 -0.02%
Market cap
4.30B
P/B
2.50
EPS
2.89
Reader sentiment Are you bullish or bearish on ITGR?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Fair Value how this is computed

Near fair value
82.17 fair value ≈ 104.89 127.61
  • Implied fair-value range of 82.17-127.61, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is +20.7% above the average-multiple fair value of 104.89.

Valuation each multiple against its own 5-year range

P/B ratio 2.50 Expensive vs history 76th percentile
5-year average 2.11 · #63 of 125 in Medical Devices
P/E ratio 34.65 In line with history 46th percentile
5-year average 36.29 · forward 32.50 · #29 of 38 in Medical Devices
P/S ratio 2.33 Expensive vs history 70th percentile
5-year average 2.07 · forward 2.30 · #60 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
Integer Holdings (ITGR) 4.30B 34.68 2.50 0.00%
Abbott Laboratories (ABT) 170.84B 31.95 3.34 2.47%
Medtronic (MDT) 109.38B 21.06 2.18 3.33%
Stryker Corp (SYK) 105.64B 28.54 4.40 1.26%
Boston Scientific (BSX) 60.26B 16.83 2.42 0.00%
Edwards Lifesciences (EW) 49.44B 49.87 4.66 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★★ Fair value147.19 Economic moatNarrow UncertaintyMedium

Trading 16.3% below Morningstar's fair value estimate.

Fair value

Integer Holdings Corp earns a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 14% discount to our quantitative fair value estimate of $147.19 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

The firm's valuation metrics increase our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its enterprise value to market value ratio of 1.3, which falls in the top 30% compared with peers globally. While highly leveraged firms can be risky, they can also be highly rewarding. This company's high enterprise value relative to its market value suggests that wise investments will yield outsize returns for investors. We believe this is a sign that shares could be undervalued.

Conversely, the company's unfavorable dividend structure is potentially concerning. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, falls in the bottom 30% globally. This could imply a planned dividend cut or relatively high share price, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.